Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 49.97M | 36.33M | 13.59M | 0.00 | 0.00 | 0.00 |
Gross Profit | 34.21M | 24.97M | 9.78M | -468.00K | -438.00K | -399.00K |
EBITDA | -82.60M | -77.43M | -46.06M | -33.07M | -25.02M | -29.22M |
Net Income | -91.72M | -85.15M | -54.81M | -36.84M | -28.03M | -32.21M |
Balance Sheet | ||||||
Total Assets | 80.25M | 107.52M | 94.48M | 124.19M | 79.04M | 109.05M |
Cash, Cash Equivalents and Short-Term Investments | 40.81M | 75.66M | 76.01M | 118.37M | 75.46M | 105.28M |
Total Debt | 52.45M | 52.69M | 40.27M | 37.37M | 17.64M | 20.21M |
Total Liabilities | 101.57M | 94.20M | 57.26M | 51.76M | 22.57M | 26.88M |
Stockholders Equity | -21.32M | 13.32M | 37.22M | 72.43M | 56.47M | 82.17M |
Cash Flow | ||||||
Free Cash Flow | -65.88M | -70.56M | -59.28M | -34.60M | -27.16M | -27.69M |
Operating Cash Flow | -65.86M | -70.54M | -59.24M | -34.58M | -27.15M | -27.69M |
Investing Cash Flow | -21.00K | 29.30M | 19.96M | -45.86M | 32.13M | -33.46M |
Financing Cash Flow | 68.19M | 70.08M | 14.85M | 77.23M | -2.53M | 60.35M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
59 Neutral | $297.40M | ― | -934.02% | ― | 107.79% | -16.01% | |
57 Neutral | $230.63M | ― | -77.51% | ― | -21.09% | 90.95% | |
56 Neutral | $684.29M | ― | -440.80% | ― | -19.56% | 35.55% | |
52 Neutral | ― | ― | ― | 44.85% | |||
51 Neutral | $7.92B | -0.43 | -41.67% | 2.21% | 22.29% | -1.85% | |
49 Neutral | $320.35M | ― | -60.25% | ― | ― | -40.03% | |
35 Underperform | $451.63M | ― | -140.33% | ― | ― | -0.69% |
On August 24, 2025, scPharmaceuticals entered into a merger agreement with MannKind Corporation, which will acquire all outstanding shares of scPharmaceuticals through a tender offer. The acquisition, valued at up to $360 million, aims to diversify and accelerate MannKind’s revenue growth, particularly with FUROSCIX, and strengthen its position in the cardiometabolic and lung disease sectors. The merger is expected to close in the fourth quarter of 2025, subject to regulatory approvals and customary conditions. This strategic move is anticipated to enhance MannKind’s market reach and integrate scPharmaceuticals’ commercial capabilities into its existing infrastructure.
On August 20, 2025, scPharmaceuticals Inc. amended its supply agreement with West Pharmaceutical Services, Inc. for the SmartDose® drug delivery system, extending the agreement’s term until December 31, 2027. The amendment outlines the company’s financial responsibilities upon termination, impacting its operational commitments and strategic partnerships in the drug delivery market.
On June 3, 2025, scPharmaceuticals Inc. held its Annual Meeting of Stockholders, with 35,156,523 shares represented, accounting for approximately 69.91% of the company’s outstanding common stock. During the meeting, William T. Abraham, M.D., Mette Kirstine Agger, and Minnie Baylor-Henry were elected as Class II Directors, and the appointment of RSM US LLP as the independent registered public accounting firm was ratified. Additionally, the compensation of the company’s named executive officers was approved on an advisory basis.